Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07457242

Probiotic Research: Open-label Functional Intervention and Longitudinal Evaluation in Healthy Adults

This study is a pre-post, open-label cohort study designed to investigate how a food-grade probiotic supplement affects biological measurements and wellbeing in healthy adults. Participants will take one capsule daily for either 1 month or 6 months.

During the study, participants will complete online cognitive tasks and provide blood and stool samples collected during home visits by trained staff. The samples will be analysed to explore changes in gut bacteria and other biological markers.

This study aims to understand whether the supplement is well tolerated and whether measurable biological changes occur. The study does not involve any experimental drugs or invasive procedures beyond blood sampling and stool collection, and participants will not be asked to change any current prescribed medications or treatments; with eligibility exclusions applying for recent antibiotics or immunosuppressants. The supplement is being studied for research purposes only and is not intended to diagnose, treat, or prevent disease. Participants will be invited to participate in a follow-up visit to assess long-term effects.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18 years or older at the time of providing informed consent.
  • In generally good health, with no known medical conditions that could interfere with the aims of the study or participant safety, as judged by self-report and screening questionnaire.
  • No history of significant psychiatric or neurological illness
  • Ability to complete study specific tasks, including:
  • Daily oral intake of a probiotic capsule
  • Self-collection of stool samples
  • Completion of online questionnaires and simple cognitive tasks
  • Able to read, understand, and communicate in English, in order to give informed consent and follow study instructions.
  • Access to the internet and a suitable device (e.g., smartphone, tablet, or computer) for completing online aspects of the study.

Exclusion criteria

  • Participants will be excluded from the study if any of the following criteria apply:
  • Use of any systemic antibiotic or systemic immunosuppressive medication within the past 8 weeks, including but not limited to:
  • β-lactam antibiotics, macrolides, tetracyclines, fluoroquinolones, aminoglycosides, glycopeptides, sulfonamides, antimycobacterial agents, systemic antifungals or antivirals
  • Use of any systemic immunosuppressants within the past 16 weeks, including, but not limited to:
  • Systemic corticosteroids, conventional immunosuppressants, biologic immunomodulators, targeted synthetic immunosuppressants, cytotoxic chemotherapy, or transplant-related immunosuppression.
  • A longer exclusion window is applied for systemic immunosuppressive therapies due to their prolonged and potentially lasting effects on immune function and gut microbial composition compared with systemic antibiotics.
  • Participants who commence systemic antibiotics or immunosuppressive therapy after enrolment will not be withdrawn from safety monitoring but will stop the supplement and will not continue the intervention phase of the study. With participant consent, data collected may still be used.
  • Major gastrointestinal disease or surgery:
  • Any history of significant gastrointestinal disease or surgery that may alter gut microbiome composition, immune function, or nutrient absorption, including but not limited to inflammatory bowel disease (Crohn's disease, ulcerative colitis, indeterminate colitis); coeliac disease or other chronic malabsorptive disorders; chronic liver, biliary, or pancreatic disease; moderate-to-severe or unstable irritable bowel syndrome; gastrointestinal malignancy; chronic gastrointestinal motility disorders; recurrent Clostridioides difficile infection; or any major gastrointestinal surgery such as bowel resection, bariatric surgery, colectomy, ileostomy or colostomy. Prior appendectomy or cholecystectomy alone is not exclusionary.
  • Current pregnancy or development of pregnancy, breastfeeding
  • Known allergy to probiotic or compounding ingredients:
  • Vitamin D3
  • Isomaltooligosaccharide
  • Yeast extract

Treatment and study plan

Probiotic supplementation (Lactobacillus plantarum)

Dietary Supplement

This probiotic is a proprietary food-grade supplement that is not yet commercially available or CE-marked.

Primary outcomes

  1. Changes in metagenome of stool samples

    Time frame: From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.

    The investigators will evaluate changes in genetic material in participant stool, representing establishment of the probiotic in the digestive tract

Secondary outcomes

  1. Change in blood multiome

    Time frame: From enrolment to the end of treatment at 4 or 24 weeks respectively. Optionally, a follow-up measure may be offered 24 weeks after the end of treatment.

    This measure will evaluate change in blood proteins (plasma proteome) and blood metabolites (plasma metabolome). Both measures are quantified using mass to charge ratio.

  2. Changes in cognition

    Time frame: Assessed weekly from enrolment and to end of treatment at 4 or 24 weeks respectively.

    Participants will complete a weekly online cognitive test administered via our remote platform. This generates a score relativised to each participant's performance, and does not utilise a scale.

  3. Change in daytime sleepiness

    Time frame: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.

    Participants will complete the Epworth Sleepiness Scale (ESS), with a minimum score of 0, and a maximum score of 24. A higher score indicates worse daytime sleepiness.

  4. Change in sleep quality

    Time frame: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.

    Participants will complete the Pittsburgh Sleep Quality Index (PSQI) survey. This has a minimum global score of 0, and a maximum of 21. A higher score indicates worse sleep quality.

  5. Change in self-reported wellbeing and mood

    Time frame: Assessed at enrolment and at end of treatment at 4 or 24 weeks respectively.

    Participants will fill out a questionnaire at the beginning and end of the study which will ask questions about subjective mood and wellbeing.

  6. Adverse event monitoring

    Time frame: Assessed from enrolment until end of treatment at 4 or 24 weeks respectively.

    Participants will be expected to self-report any adverse features resulting from use of the supplement

Study contacts

Contact information is provided by the study sponsor or research team.

Research Team

CONTACT

[email protected]

+44 7757 056785

Sponsors and collaborators

Lead sponsor

OneCarbon

Industry

Registry information

Acronym: PROFILE

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Mar 9, 2026
Registry last updated
Mar 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.